Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on December 21, 2021. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The report discloses a strategic business development regarding market access and technology expansion.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes
- Strategic Partnership: The Company appointed a leading healthcare management firm to enhance its market access strategy.
- Operational Expansion: The appointment supports the expansion of the installation base for the Company's signal processing technology used in arrhythmia care.
Guidance, Outlook, and Risks
Management Commentary: The press release (Exhibit 99.1) highlights the strategic intent to improve market access. The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached.
Regulatory Note: The information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The Company notes that furnishing this information is not intended to constitute a determination that the information is material or required by Regulation FD.
Investor Verification Checklist
- Verify the identity of the "leading healthcare management firm" appointed in the press release (Exhibit 99.1).
- Review the specific terms of the engagement and any associated costs or revenue-sharing models not detailed in this summary.
- Confirm the current status of the signal processing technology installation base and recent growth rates.
- Check subsequent filings for any updates on the market access strategy, as the Company disclaims an obligation to update this specific report.